Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice

Drug Metabolism and Disposition(2024)10.1124/dmd.123.001607Source: DataRank Database

Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice is a research paper published in Drug Metabolism and Disposition (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

refseq

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.86)OA: hybridTopics (66)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Katherine D. Lynch ORCID,Victoria O. Oyanna ORCID,M. Call,Laura A. White,Tyler N. Graf ORCID

Live enrichment

PubMed:38485280 PMC:PMC11023818 OpenAlex:https://openalex.org/W4392819206

NCCIH NIH HHS

Grant: R56 AT010650

National Institutes of Health

Grant: 1R56AT010650-01A1

Risk of xenobiotic-drug interactions in chronic disease

FWCI

0.86

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://dmd.aspetjournals.org/content/dmd/early/2024/03/14/dmd.123.001607.full.pdf

publisherhttps://dmd.aspetjournals.org/content/dmd/early/2024/03/14/dmd.123.001607.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0090955624011577?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0090955624011577?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/dmd.123.001607

Fields of Study

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseasePancreatic function and diabetesHumansMaleFemaleMiceAnimalsNon-alcoholic Fatty Liver DiseaseMice, TransgenicSolute Carrier Organic Anion Transporter Family Member 1B3Liver-Specific Organic Anion Transporter 1LiverOrganic Anion TransportersMembrane Transport ProteinsSilymarinDrug Interactions

MeSH Terms

Solute Carrier Organic Anion Transporter Family Member 1B3AnimalsDrug InteractionsFemaleHumansLiverMaleMice, TransgenicSilymarinMembrane Transport ProteinsOrganic Anion TransportersLiver-Specific Organic Anion Transporter 1MiceNon-alcoholic Fatty Liver Disease

Keywords

Nonalcoholic fatty liver diseaseTransgeneHumanized mousePharmacokineticsGenetically modified mouseFatty liverPharmacologyLiver diseaseDiseaseMedicineBiologyImmunologyInternal medicineGeneBiochemistryMale570Science & TechnologyLiver-Specific Organic Anion Transporter 1Organic Anion TransportersMembrane Transport ProteinsMice, TransgenicArticlesMiceSolute Carrier Organic Anion Transporter Family Member 1B3LiverNon-alcoholic Fatty Liver Disease615HumansAnimalsFemaleDrug InteractionsPharmacology & PharmacyLife Sciences & BiomedicineSilymarin

Sustainable Development Goals

SDG 0: Good health and well-being

Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice

FAIR Checklist

Authors (8)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)